Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 15, 2016Pharmacogenomics

Clinical Impact of the CYP3A5 6986A>G Allelic Variant on Kidney Transplantation Outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAdrien FlahaultDADany AnglicheauMLMarie‐Anne Loriot

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Flahault et al. (2016) studied this question.

synapsesocial.com/papers/6a9635efe011ca463da13938https://doi.org/10.2217/pgs-2016-0146
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Specificity of Histological Markers of Long-Term CNI Nephrotoxicity in Kidney-Transplant Recipients Under Low-Dose Cyclosporine Therapy2011 · 116 citations
  2. 2Calcineurin Inhibitor Nephrotoxicity2009 · 1,500 citations
  3. 3The Influence of Pharmacogenetics on the Time to Achieve Target Tacrolimus Concentrations after Kidney Transplantation2004 · 258 citations
  4. 4Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 22003 · 300 citations
  5. 5CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation2011 · 81 citations